Analysts See $0.03 EPS for Knight Therapeutics Inc. (GUD)

July 14, 2018 - By Elizabeth Jones

Knight Therapeutics Inc. (TSE:GUD) Logo

Analysts expect Knight Therapeutics Inc. (TSE:GUD) to report $0.03 EPS on August, 9.T_GUD’s profit would be $4.29M giving it 71.75 P/E if the $0.03 EPS is correct. After having $0.05 EPS previously, Knight Therapeutics Inc.’s analysts see -40.00 % EPS growth. The stock increased 0.47% or $0.04 during the last trading session, reaching $8.61. About 64,022 shares traded. Knight Therapeutics Inc. (TSE:GUD) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company has market cap of $1.23 billion. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. It has a 68.33 P/E ratio. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.